Expertise in
5
conditions

Hiroaki Umebayashi

Sendai, JP 
Expertise in
5
conditions
Sendai, JP 

Overview

Hiroaki Umebayashi practices practicing medicine in Sendai, Japan.

Mr. Umebayashi is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Arthritis, Muckle-Wells Syndrome, and Familial Cold Autoinflammatory Syndrome.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Sendai, Japan
Other Locations
Japan
Kagoshima, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

27 Total Publications

Validation of the 2019 EULAR/ACR classification criteria and clinical characteristics of childhood-onset Japanese patients with systemic lupus erythematosus.
Validation of the 2019 EULAR/ACR classification criteria and clinical characteristics of childhood-onset Japanese patients with systemic lupus erythematosus.
Journal: Modern rheumatology
Published: July 11, 2025

Frequently Asked Questions about Hiroaki Umebayashi

Is Hiroaki Umebayashi a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Hiroaki Umebayashi is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hiroaki Umebayashi participate in research or clinical trials?

Yes. Hiroaki Umebayashi has published 27 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Hiroaki Umebayashi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Umebayashi's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile